Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities
Authors:
Open Access
- 10 November 2021
- journal article
- research article
- Published by S. Karger AG in Gerontology
- Vol. 68 (8) , 910-916
Abstract
Background: Older adults living in long-term care facilities (LTCFs) are at increased risk for severe outcomes from COVID-19 and were identified as a priority group in COVID-19 vaccination strategies. Emerging evidence suggests vaccine effectiveness in LTCF populations, but data about median and long-term durability of immune response after vaccination are still limited. Objectives: In this study, we assessed the humoral response to BNT162b2 mRNA COVID-19 vaccine 3 months after the second dose, in a cohort of 495 residents aged ≥65 years from 11 LTCF in Granada, Spain. Method: Between April 19 and April 30, 2021, we measured anti-SARS-CoV-2 Spike IgG to evaluate the humoral vaccination response. Antibody titers were reported in binding antibody units (BAU/mL). Bivariate and multivariate logistic regression models were performed to investigate the impact of age, sex, underlying health conditions, and prior COVID-19 infection on the antibody levels. Results: Over 96% of the participants developed an adequate humoral response. We detected higher antibody titers in previously infected individuals, compared with those previously uninfected (B: 1,150.059 BAU/mL, p < 0.001). Moreover, we found a significant inverse association between age and antibody levels (B: −7.943 BAU/mL, p < 0.05). This negative age-dependent response was more noticeable among residents over 85 years old. In contrast, baseline health conditions and cognitive status were not associated with different antibody levels. Conclusions: These findings support monitoring COVID-19 vaccination response trend in older adults, in order to optimize future disease prevention and control strategies in this vulnerable population.Keywords
This publication has 13 references indexed in Scilit:
- Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort studyThe Lancet Infectious Diseases, 2021
- Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021Eurosurveillance, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home ResidentsClinical Infectious Diseases, 2021
- Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 VaccinationClinical Infectious Diseases, 2021
- WHO International Standard for anti-SARS-CoV-2 immunoglobulinThe Lancet, 2021
- Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID‐A studyJournal of the American Geriatrics Society, 2021
- Influence of immune aging on vaccine responsesJournal of Allergy and Clinical Immunology, 2020
- Defining and measuring multimorbidity: a systematic review of systematic reviewsEuropean Journal of Public Health, 2018
- Immune Response to Viruses: Antibody-Mediated Immunity2008